Introducing The Pioneering XTRAC Velocity Excimer Laser: Delivers Psoriasis And Vitiligo Treatments Three Times Faster

Breakthrough Device Can Cover a Significantly Higher Percentage of a Person`s
Body Surface Per Session, Providing Practical Alternative to Pharmaceuticals,
Biologics or Full-Body Phototherapy

MONTGOMERYVILLE, Pa.--(Business Wire)--
PhotoMedex, Inc. (NASDAQ: PHMD), a leader in the development of proprietary
excimer laser and fiber optic systems as well as other products for
dermatological applications, today announced the availability of its
groundbreaking XTRAC Velocity Excimer Laser, a device expected to redefine laser
treatment options for patients suffering from psoriasis and vitiligo.

Two separate independent third-party agencies have confirmed that the XTRAC
Ultra® laser, precursor to the XTRAC Velocity excimer laser, is the most
accurate, powerful, and fastest excimer laser available to date. PhotoMedex has
raised the bar even higher with the Velocity laser, which features an average
laser power of up to 7.2 watts delivered to the patient. Velocity`s treatment
time is nearly three times faster than PhotoMedex` XTRAC Ultra laser. In
performance tests the device has been able to treat lesions of 3,500 cm2 (600
mj/cm2) in 4 minutes, 52 seconds*-roughly 1/3 the time required by the Ultra.

Because the innovative Velocity excimer laser can cover a much greater surface
area in the average treatment session-up to 20% of the body surface in five
minutes versus only 2 to 4% for alternative lasers-it is the first practical
alternative to potent pharmaceuticals or full-body UV irradiation for patients
with severe psoriasis.

"The XTRAC Velocity laser is going to be a game-changer for patients and
dermatology practices alike," said Jeff O`Donnell, president of PhotoMedex. "For
patients, the Velocity will dramatically shorten treatment times, increase the
size and number of lesions that can be treated per session, and open laser
therapy as a viable alternative for patients who were not necessarily laser
candidates in the past. In fact, for busy dermatology practices, the Velocity
will make it practical to treat as many as 32 patients per day."

New Touchscreen, Handpiece Controls

With a maximum repetition rate of 400 Hz and delivered laser energy of 12 to 18
millijoules/pulse, PhotoMedex` XTRAC Velocity is unparalleled in its power and
treatment speed. The new laser system has an unparalleled safety profile and is
also highly effective with a long duration of remission-yet laser performance is
only the beginning of the unit`s advantages.

To increase quality of care for patients as well as increase the clinician`s
convenience, the Velocity offers a new full-color touchscreen control interface.
The screen and built-in database tracking software goes beyond normal equipment
operation to incorporate patient information including ID generation,
recognition, treatment history, dosing heuristics and more. Also included for
the first time on the Velocity is a touch control handpiece that allows the
laser treatment to be delivered more easily compared to conventional
footswitch-controlled devices.

"Profit Per Treatment" Model

Like all the excimer lasers in the PhotoMedex line, the Velocity is available to
clinics at no direct cost via a unique consignment-based business model. Thanks
to the "Profit per Treatment" model, dermatologists provide Velocity laser
therapy to their customers, paying a fee only on treatments rendered. In-service
training is provided by a dedicated PhotoMedex clinical specialist.
Reimbursement support is also provided by a team of direct employee-insurance
specialists who continue to receive positive reviews from both office staff and
patients for their dedicated and knowledgeable support. Purchase options and
financing for PhotoMedex lasers are available as well.

For full details about the new PhotoMedex XTRAC Velocity excimer laser, call
1-877-44-XTRAC or email cust@photomedex.com.

* Treatment time calculations do not include the overhead associated with moving
the hand piece.

About PhotoMedex:

PhotoMedex offers a wide range of products and services across multiple
specialty areas, including dermatology, urology, gynecology, orthopedics and
other surgical specialties. PhotoMedex is a leader in the development,
manufacturing and marketing of medical laser products and services. PhotoMedex
also develops and markets products based on its patented, clinically proven
Copper Peptide technology for skin health, hair care and wound care. PhotoMedex
sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons
and through licenses with strategic partners into the consumer market, including
a long-term worldwide license agreement with Neutrogena, a Johnson & Johnson
company. ProCyte brands include Neova, Ti-Silc, VitalCopper, Simple Solutions
and AquaSante.

In addition, as a result of the recent merger with Photo Therapeutics,
PhotoMedex now researches, develops and manufactures non-laser light devices for
the treatment of clinical and aesthetic dermatological conditions and adds the
Omnilux products to its arsenal. The Omnilux products incorporate a new
technology based on narrowband Light Emitting Diodes (LEDs) to treat a wide
range of dermatological conditions including acne, photodamage, skin
rejuvenation, psoriasis, post-surgery wound healing and non-melanoma skin
cancer.

Safe Harbor Statement

Some portions of this release, particularly those describing PhotoMedex`
strategies contain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1993, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those
goals, actual results could differ materially from those projected in the
forward-looking statements as a result of a number of factors, including
difficulties in marketing its products and services, need for capital,
competition from other companies and other factors, any of which could have an
adverse effect on the business plans of PhotoMedex, its reputation in the
industry or its results.In light of significant uncertainties inherent in
forward-looking statements included herein, the inclusion of such statements
should not be regarded as a representation by PhotoMedex or its subsidiaries
that the forward-looking statements will be achieved.

SS|PR
Press Contact:
Belinda Banks
609/750-9110
Belinda@sspr.com

Copyright Business Wire 2009